There are other reports of similar mutation rates in the PI3K/AKT pathway, but mostly in metastatic disease [4], and in these studies there was no gene or pathway that was consistently mutated outside of the androgen signaling pathway
There are other reports of similar mutation rates in the PI3K/AKT pathway, but mostly in metastatic disease [4], and in these studies there was no gene or pathway that was consistently mutated outside of the androgen signaling pathway. the 40 tumors evaluable for mutations, 10% had point mutations in potentially actionable cancer genes. Of the…